Welcome to our dedicated page for Zelira Therapeutics news (Ticker: ZLDAF), a resource for investors and traders seeking the latest updates and insights on Zelira Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Zelira Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Zelira Therapeutics's position in the market.
Zelira Therapeutics has launched ZYRAYDI™, a patented technology that transforms cannabis distillate into a free flow powder matrix, facilitating the production of pharmaceutical-grade capsules and tablets. This Enhanced Distillate Capture and Dissolution Matrix (EDCDM) addresses formulation challenges and improves dissolution rates, potentially enhancing the acceptance of cannabinoid medicines. ZYRAYDI™ is cost-effective, adaptable, and utilizes FDA-approved ingredients. Zelira's cannabinoid products target various medical conditions, generating revenues from its proprietary formulations in select markets.
Zelira Therapeutics Ltd (ASX: ZLD, OTCQB: ZLDAF) announced that its insomnia medication, Zenivol™, has received approval from Germany's regulatory authority BfArM for launch in the medical cannabis market. This marks a significant milestone as Germany is a major market for cannabinoid-based medicines. Zenivol™ is the world's first clinically validated cannabis-based pharmaceutical sleep medication, already available in Australia. The company aims to collaborate with Adjupharm for its launch in Germany and plans to license Zenivol™ in other global markets.
Zelira Therapeutics Ltd (OTCQB: ZLDAF) launched its RAF FIVE™ acne treatment product line in the US through its dermatology subsidiary, Ilera Derm LLC. This line targets the $11 billion global acne medication market and includes five products enriched with skincare ingredients such as hyaluronic acid and peptides. The unique formulation features Zylorma®, a patent-pending complex developed in collaboration with Dr. Karyn Grossman, utilizing CBD and salicylic acid to combat acne. Initial consumer studies indicate significant improvement in acne symptoms within just seven days.
FAQ
What is the current stock price of Zelira Therapeutics (ZLDAF)?
What is the market cap of Zelira Therapeutics (ZLDAF)?
